Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Latuda
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-128679 · Präparat HOS-096607
6
Potential for lurasidone to affect other medicinal products
Coadministration of lurasidone with midazolam, a sensitive CYP3A4 substrate, resulted in a < 1.5-fold
increase in midazolam exposure. Monitoring is recommended when lurasidone and CYP3A4
substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide,
quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) are coadministered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage 2e1666caac05dec018ade00abe2dbf9f4c961d477b3ca68f891d42b02936f3a0 · Zeichen 4017–4462 im Abschnitt
Gegenanzeigen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 5–6
HOS-130910 · Präparat HOS-096981
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
5
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
• Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration phase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage a6fe4a49e4c7e3e416db9488a60b10861c79e9736141c4f5c1792a87a1df0b1c · Zeichen 509–952 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 15–16
HOS-130961 · Präparat HOS-096981
15
Ergot derivatives
Ergot alkaloids (including but Although not studied, voriconazole Contraindicated (see section
not limited to: ergotamine and is likely to increase the plasma 4.3)
dihydroergotamine) concentrations of ergot alkaloids
[CYP3A4 substrates] and lead to ergotism.
GI motility agents
Cisapride Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of cisapride 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Herbal medicines
St. John’s Wort In an independent published study, Contraindicated (see section
[CYP450 inducer; Voriconazole AUC0-∞ ↓ 59% 4.3)
P-gp inducer]
300 mg TID (coadministered
with voriconazole 400 mg
single dose)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) ergot alkaloids (HOS-108807) lead (HOS-085592) ergotamine (HOS-086154) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage 608716cb9321055b957704555629a388b6871aa57a4894886dbdf0126dc8f2ab · Zeichen 22264–23205 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-131695 · Präparat HOS-097124
Ceritinib has been classified in vivo as a strong CYP3A4 inhibitor and has the potential to interact with
medicinal products that are metabolised by CYP3A, which may lead to increased serum
concentrations of the other product. Co-administration of a single dose of midazolam (a sensitive
CYP3A substrate) following 3 weeks of ceritinib dosing in patients (750 mg daily fasted) increased
the midazolam AUCinf (90% CI) by 5.4-fold (4.6, 6.3) compared to midazolam alone.
Co-administration of ceritinib with substrates primarily metabolised by CYP3A or CYP3A substrates
known to have narrow therapeutic indices (e.g. alfuzosin, amiodarone, cisapride, ciclosporin,
dihydroergotamine, ergotamine, fentanyl, pimozide, quetiapine, quinidine, lovastatin, simvastatin,
sildenafil, midazolam, triazolam, tacrolimus, alfentanil and sirolimus) should be avoided and
alternative medicinal products that are less sensitive to CYP3A4 inhibition should be used if possible.
If unavoidable, dose reduction for co-administered medicinal products that are CYP3A substrates with
narrow therapeutic indices should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfentanil (HOS-109375) alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) simvastatin (HOS-086158) quinidine (HOS-085593) lead (HOS-085592) tacrolimus (HOS-085202) pimozide (HOS-085600) sirolimus (HOS-085172) sildenafil (HOS-086162) fentanyl (HOS-086196) ergotamine (HOS-086154) amiodarone (HOS-085596) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 8c077815baee1cc86d1631acdc9514aeea609ffa511fd705feb86861d6e3d369 · Zeichen 3957–5064 im Abschnitt
Wechselwirkungen · Zykadia
Zykadia 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 34
HOS-131749 · Präparat HOS-097124
Ceritinib has been classified in vivo as a strong CYP3A4 inhibitor and has the potential to interact with
medicinal products that are metabolised by CYP3A, which may lead to increased serum
concentrations of the other product. Co-administration of a single dose of midazolam (a sensitive
CYP3A substrate) following 3 weeks of ceritinib dosing in patients (750 mg daily fasted) increased
the midazolam AUCinf (90% CI) by 5.4-fold (4.6, 6.3) compared to midazolam alone.
Co-administration of ceritinib with substrates primarily metabolised by CYP3A or CYP3A substrates
known to have narrow therapeutic indices (e.g. alfuzosin, amiodarone, cisapride, ciclosporin,
dihydroergotamine, ergotamine, fentanyl, pimozide, quetiapine, quinidine, lovastatin, simvastatin,
sildenafil, midazolam, triazolam, tacrolimus, alfentanil and sirolimus) should be avoided and
alternative medicinal products that are less sensitive to CYP3A4 inhibition should be used if possible.
If unavoidable, dose reduction for co-administered medicinal products that are CYP3A substrates with
narrow therapeutic indices should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfentanil (HOS-109375) alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) simvastatin (HOS-086158) quinidine (HOS-085593) lead (HOS-085592) tacrolimus (HOS-085202) pimozide (HOS-085600) sirolimus (HOS-085172) sildenafil (HOS-086162) fentanyl (HOS-086196) ergotamine (HOS-086154) amiodarone (HOS-085596) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-29T12:25:00Z · SHA-256 0b1dbf25bbec546abc5492b7ae4f6a782b99bf34d000b6651bc6bf57cbe85e06 · Passage 8c077815baee1cc86d1631acdc9514aeea609ffa511fd705feb86861d6e3d369 · Zeichen 3957–5064 im Abschnitt
Wechselwirkungen · Raxone
Raxone 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 3–4
HOS-132020 · Präparat HOS-097176
3
were administered together. After repeated administration Cmax and AUC of midazolam were increased
by 28% and 34%, respectively, when midazolam was administered in combination with 300 mg
idebenone t.i.d. Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as
alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus,
tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in
patients receiving idebenone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) ergot alkaloids (HOS-108807) tacrolimus (HOS-085202) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-20T15:23:00Z · SHA-256 27500298ab701035c3441bc2480ad7b892adfeab7238f85574eb8e5a529c19e1 · Passage 9a05a3b0d707914465607ca103e0f407d599a8f7b1a14726958377862cd7376e · Zeichen 660–1181 im Abschnitt
Wechselwirkungen · Zydelig
Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-132106 · Präparat HOS-097192
Alternative medicinal products, such
as olanzapine, may be considered.
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan ↑ serum concentrations Caution should be exercised and
patients closely observed for bosentan-
related toxicity.
ERGOT ALKALOIDS
Ergotamine, dihydroergotamine ↑ serum concentrations Idelalisib should not be
co-administered with ergotamine or
dihydroergotamine.
GASTROINTESTINAL MOTILITY AGENTS
Cisapride ↑ serum concentrations Idelalisib should not be
co-administered with cisapride.
GLUCOCORTICOIDS
Inhaled/nasal corticosteroids:
Budesonide, fluticasone ↑ serum concentrations Clinical monitoring is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) fluticasone (HOS-108914) cisapride (HOS-085610) ergot alkaloids (HOS-108807) budesonide (HOS-086332) ergotamine (HOS-086154) bosentan (HOS-086291) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-21T17:52:00Z · SHA-256 f55f90ba278a87ef1c8e7162344ed4bd66ac7180deaf4c8fda3eca5bbf8e87e5 · Passage 3bc5dd16d11d17191775a3e4049c2785427ec9be009ef5c94fd6d9a10a26f310 · Zeichen 8272–9312 im Abschnitt
Wechselwirkungen · Ibrance
IBRANCE 75 mg hard capsules IBRANCE 100 mg hard capsules IBRANCE 125 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-132447 · Präparat HOS-097230
The dose of sensitive CYP3A substrates with a narrow therapeutic index (e.g., alfentanil, cyclosporine,
dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus)
may need to be reduced when coadministered with IBRANCE as IBRANCE may increase their
exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) cyclosporine (HOS-084512) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage 3fd153a2a90e02d00d06881d2e93579b144e519dc3f8998d2749fdaf6492a94f · Zeichen 3027–3327 im Abschnitt
Wechselwirkungen · Ibrance
IBRANCE 75 mg film-coated tablets IBRANCE 100 mg film-coated tablets IBRANCE 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-132501 · Präparat HOS-097230
The dose of sensitive CYP3A substrates with a narrow therapeutic index (e.g., alfentanil, cyclosporine,
dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus)
may need to be reduced when coadministered with IBRANCE as IBRANCE may increase their
exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) cyclosporine (HOS-084512) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-07T16:43:00Z · SHA-256 73a98bcaed2e5b347266ff9f037099270b545348fdf729a2479eedc3e06fd319 · Passage 3fd153a2a90e02d00d06881d2e93579b144e519dc3f8998d2749fdaf6492a94f · Zeichen 2583–2883 im Abschnitt
Gegenanzeigen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-132828 · Präparat HOS-097310
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1;
- Hypersensitivity to any imidazole antifungal medicinal product;
- Acute or chronic liver disease and/or if pre-treatment liver enzymes levels are above 2 times the upper
limit of normal (see sections 4.2 and 4.4):
- Pregnancy (see section 4.6);
- Breastfeeding (see section 4.6);
- Congenital or documented acquired QTc prolongation ;
- Concomitant therapy with any of the following medicinal products which may interact and result in
potentially life-threatening adverse reactions (see section 4.5):
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and
lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential:
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir
(saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and
methylergometrine (methylergonovine) due to an increased risk of ergotism and other serious
vasospastic adverse reactions;
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk
of hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) imidazole (HOS-117862) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) ergotamine (HOS-086154) ritonavir (HOS-084521) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage f9d16641f2e5b06b321fa0c79f0dacdfede818d20585398b4d37ddb19dad6a14 · Zeichen 0–2044 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132842 · Präparat HOS-097310
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin)
due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential :
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir
1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine
(methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse
reactionsevents
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of
hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of
these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) solifenacin (HOS-116433) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) ombitasvir (HOS-110300) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) colchicine (HOS-086147) everolimus (HOS-086310) fesoterodine (HOS-116432) sirolimus (HOS-085172) ergotamine (HOS-086154) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) ranolazine (HOS-086141) irinotecan (HOS-112102) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 0b65d259964c6f340994be44a864bad55b31283e3fc412d0d5a47323a792d889 · Zeichen 171–2105 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-132857 · Präparat HOS-097310
9
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Telithromycin Telithromycine: Not recommended.
Clarithromycin AUC: ↑ 2-fold Contraindicated in patients with
Cmax: ↑1.5-fold severe renal impairment due to the
Potential ↑in plasma concentrations of risk of QT interval prolongation and
clarithromycin serious hepatic adverse reactions (see
section 4.3).
Isavuconazole AUC: ↑ 5-fold Not recommended due to increased
Cmax: ↑ 1.1 -fold risk of isavuconazole adverse
reactions, please consult
isavuconazole SmPC
Praziquantel ↑in plasma concentrations of Careful monitoring.
praziquantel have been observed Dose adjustment of praziquantel
may be required.
Antimigraine Drugs
Ergots alkaloids such as Potential ↑in plasma concentrations of Contraindicated due to the increased
dihydroergotamine, ergot alkaloids risk of ergotism and other serious
ergometrine vasospastic adverse reactions (see
(ergonovine), section 4.3).
ergotamine,
methylergometrine
(methylergonovine)
Eletriptan Eletriptan: Not recommended.
AUC: ↑ 5.9-fold
Cmax: ↑ 2.7-fold
Antineoplastics
Irinotecan Irinotecan: Contraindicated due to an alteration
AUC: ↑ 2.1-fold of the metabolism of this medicinal
product (see section 4.3).
Sunitinib Sunitinib Not recommended due to the risk of
Dasatinib AUC: ↑ 1.5-fold increased exposure to these medicinal
Lapatinib Cmax: ↑ 1.5-fold products and QT prolongation.
Nilotinib Lapatinib:
Erlotinib AUC: ↑ 3.6-fold
Dabrafenib Nilotinib:
Cabozantinib AUC: ↑ 3.0-fold
Erlotinib:
AUC: ↑ 1.9-fold
Cmax: ↑ 1.7-fold
Dasatinib
↑in plasma concentrations of
Dasatinib have been observed
Dabrafenib
AUC: ↑ 1.7-fold
Cmax: ↑ 1.3-fold
Cabozantinib
AUC: ↑ 1.4-fold
Cmax: ↔
Ibrutinib Ibrutinib: Not recommended as it may increase
AUC: ↑ 24-fold ibrutinib-related toxicity.
Cmax: ↑ 29-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): praziquantel (HOS-132858) dasatinib (HOS-086217) isavuconazole (HOS-085186) methylergonovine (HOS-086155) dabrafenib (HOS-109452) ergot alkaloids (HOS-108807) telithromycin (HOS-084523) lapatinib (HOS-122565) clarithromycin (HOS-084517) erlotinib (HOS-113527) eletriptan (HOS-132859) sunitinib (HOS-109453) ergotamine (HOS-086154) irinotecan (HOS-112102) ergonovine (HOS-086153) cabozantinib (HOS-109450) nilotinib (HOS-086218) dihydroergotamine (HOS-086152) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 03def5869df8cb542da23a60d098a55dd2a7a8fe93c7c4d29a7dfa3bc81a0b64 · Zeichen 11575–15074 im Abschnitt
Gegenanzeigen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-133892 · Präparat HOS-097520
Co-administration with medicinal products that are highly dependent on CYP3A for clearance and for
which elevated plasma concentrations are associated with serious or life-threatening adverse reactions.
Therefore, Genvoya should not be co-administered with medicinal products that include, but are not
limited to, the following (see sections 4.4 and 4.5):
• alpha 1-adrenoreceptor antagonists: alfuzosin
• antiarrhythmics: amiodarone, quinidine
• ergot derivatives: dihydroergotamine, ergometrine, ergotamine
• gastrointestinal motility agents: cisapride
• HMG Co-A reductase inhibitors: lovastatin, simvastatin
• lipid-modifying agent: lomitapide
• neuroleptics/antipsychotics: pimozide, lurasidone
• PDE-5 inhibitors: sildenafil for the treatment of pulmonary arterial hypertension
• sedatives/hypnotics: orally administered midazolam, triazolam
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 0f88e646d6d04d22e82ffc09fef77e923a5508a7e7714d22031d9defc05e872d · Zeichen 94–985 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-133928 · Präparat HOS-097520
Co-administration of Genvoya and some medicinal products that are primarily metabolised by CYP3A
may result in increased plasma concentrations of these products, which are associated with the
potential for serious or life-threatening adverse reactions such as peripheral vasospasm or ischaemia
(e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g.,
simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally
administered midazolam or triazolam). Co-administration of Genvoya and other medicinal products
primarily metabolised by CYP3A such as amiodarone, lomitapide, quinidine, cisapride, pimozide,
lurasidone, alfuzosin and sildenafil for pulmonary arterial hypertension is contraindicated (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 4dadcf172c034e4a296aebd72b2538a7bc83a7607f8e8d78e400d88f4a537379 · Zeichen 4154–4947 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5
HOS-134441 · Präparat HOS-097580
Co-administration of darunavir with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) bepridil (HOS-085612) quinidine (HOS-085593) domperidone (HOS-114656) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0623acf1b29e890c85fc94e283370387704b0e29df5d70432cea48b4e0948b1f · Zeichen 452–1192 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 44
HOS-134580 · Präparat HOS-097580
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the co-
administered medicinal product. Therefore, concomitant treatment with such medicinal products for
which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cobicistat (HOS-088111) bepridil (HOS-085612) quinidine (HOS-085593) grazoprevir (HOS-108815) ivabradine (HOS-109426) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) ranolazine (HOS-086141) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage dc54d993409459377eca2778cf25b8655b8f68649a72da054ab0f0fc3b77b4d4 · Zeichen 1379–2234 im Abschnitt
Wechselwirkungen · Kisqali
Kisqali 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-136229 · Präparat HOS-097860
Concomitant administration of ribociclib with the following CYP3A4 substrates should be avoided:
alfuzosin, amiodarone, cisapride, pimozide, quinidine, ergotamine, dihydroergotamine, quetiapine,
lovastatin, simvastatin, sildenafil, midazolam, triazolam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:22:00Z · SHA-256 808e9743b462916472557a0fc0a032e5a4cdf4c2e48d8fd0f992823e92cc05c1 · Passage f9a5770bcb9b3257ad41890cbeac7b97c37534e300399d6f7a156c847b5319dd · Zeichen 5810–6063 im Abschnitt
Wechselwirkungen · Rubraca
Rubraca 200 mg film-coated tablets Rubraca 250 mg film-coated tablets Rubraca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-137464 · Präparat HOS-098043
6
CYP3A substrates
Rucaparib increased midazolam Cmax by 1.13 fold (90% CI: 0.95 to 1.36) and AUCinf by 1.38 fold
(90% CI: 1.13 to 1.69). Caution is advised when co-administering medicinal products that are CYP3A
substrates with a narrow therapeutic index (e.g., alfentanil, astemizole, cisapride, cyclosporine,
dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine).
Dose adjustments may be considered, if clinically indicated based on observed adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) cisapride (HOS-085610) quinidine (HOS-085593) tacrolimus (HOS-085202) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) fentanyl (HOS-086196) ergotamine (HOS-086154) terfenadine (HOS-085607) cyclosporine (HOS-084512) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-27T16:36:00Z · SHA-256 230a9c1df880b14750043bea049c21874a6e3d04bb3b18b3f15c92b0c4aa3f16 · Passage f00322b90d3abf5ab7772bb0ab09e3915a8eae462168b1888a58fb2ce822c41c · Zeichen 2814–3322 im Abschnitt
Gegenanzeigen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-138460 · Präparat HOS-098200
Co-administration with medicinal products such as those products listed below due to the potential for
serious and/or life-threatening adverse reactions (see section 4.5):
- alfuzosin
- amiodarone, dronedarone, ivabradine, quinidine, ranolazine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- rifampicin
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- dapoxetine
- domperidone
- naloxegol
- pimozide, quetiapine, sertindole, lurasidone (see section 4.5)
- elbasvir/grazoprevir
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d5339bf98a1f0c8c12e608ac2e03423cce35d78a9e0bb8d544d94fd38d39e9f0 · Zeichen 452–1349 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-138493 · Präparat HOS-098200
14
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Based on theoretical considerations Co-administration of Symtuza
bosentan is expected to decrease and bosentan is not
darunavir and/or cobicistat plasma recommended.
concentrations.
(CYP3A induction)
Symtuza is expected to increase
bosentan plasma concentrations.
(CYP3A inhibition)
ERGOT DERIVATIVES
e.g. Based on theoretical considerations Co-administration of Symtuza
Dihydroergotamine DRV/COBI may increase ergot and ergot derivatives is
Ergometrine derivative exposure. contraindicated (see section 4.3).
Ergotamine
Methylergonovine
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A inhibitors
Elbasvir/grazoprevir Based on theoretical considerations Concomitant use of Symtuza with
Symtuza may increase the elbasvir/grazoprevir is
exposure to grazoprevir. contraindicated (see section 4.3).
(OATP1B and CYP3A inhibition)
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
DRV/COBI may increase the co-administer Symtuza with
exposure to glecaprevir and glecaprevir/pibrentasvir.
pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
Daclatasvir Based on theoretical Symtuza and sofosbuvir,
Ledipasvir considerations, no clinically sofosbuvir/ledipasvir, or
Sofosbuvir relevant interaction is expected. daclatasvir can be used
concomitantly without dose
adjustment
Herbal products
St. John’s Wort (Hypericum
Based on theoretical consideration, The concomitant use of Symtuza
perforatum) St. John’s Wort may substantially with these medicinal products is
decrease DRV/COBI (CYP3A4 contraindicated (see section 4.3).
induction) and TAF exposures.
(P-gp induction)
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin Atorvastatin (10 mg once daily): Concomitant use of a HMG CoA
Fluvastatin atorvastatin AUC ↑ 290% reductase inhibitor and Symtuza
Pitavastatin atorvastatin Cmax ↑ 319% may increase plasma
Pravastatin atorvastatin Cmin ND concentrations of the lipid
Rosuvastatin lowering agent, which may lead
Rosuvastatin (10 mg once daily): to adverse reactions such as
rosuvastatin AUC ↑ 93% myopathy.
rosuvastatin Cmax ↑ 277% When administration of
rosuvastatin Cmin ND HMG CoA reductase inhibitors
and Symtuza is desired, it is
Based on theoretical considerations recommended to start with the
DRV/COBI is expected to increase lowest dose and titrate up to the
the plasma concentrations of desired clinical effect while
fluvastatin, pitavastatin, monitoring for safety.
pravastatin, lovastatin and
Lovastatin simvastatin. Concomitant use of Symtuza with
Simvastatin (CYP3A inhibition and/or lovastatin and simvastatin is
transport) contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) methylergonovine (HOS-086155) daclatasvir (HOS-119742) sofosbuvir (HOS-108928) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) ledipasvir (HOS-110493) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) lead (HOS-085592) grazoprevir (HOS-108815) ergotamine (HOS-086154) bosentan (HOS-086291) dihydroergotamine (HOS-086152) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 7dedc11142e46d7502bc7e251f11ffb3c178eac67ce8ce16fb9ccc902e5f3904 · Zeichen 28527–32949 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.